East Coast, USA-based Karyopharm Therapeutics (Nasdaq: KPTI) has announced positive top-line results from the Phase III BOSTON study of Xpovio (selinexor).
Shares in the oncology-focused biotech leapt 70% on Monday, as investors digested results from the study, which examined an Xpovio-based combination therapy as an option against multiple myeloma in a later-line setting.
People with multiple myeloma were given Xpovio plus once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd), in comparison with standard twice-weekly Velcade plus low-dose dexamethasone (Vd).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze